DNA methylation studies of CpGs in the TET2 upstream promotor region across both NHL tumour-derived and control PBMC samples showed consistently low levels of methylation, and a similar trend was observed in the methylation of genomic DNA in the NHL case-control cohort. The gene discussed is TET2; the disease is non-Hodgkin lymphoma.